Table 1.
Percent change (PC)a in age‐standardized, delay-adjusted incidence rates from 2019 to 2020 by cancer site and sex, using the November 2022 data submission
| Males |
Females |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2019 rate | 2020 rate | PC | 95% PC upper CI | 95% PC lower CI | 2019 rate | 2020 rate | PC | 95% PC upper CI | 95% PC lower CI | |
| All sites | 499.1 | 451.2 | −9.6% | −10.0% | −9.2% | 432.6 | 392.5 | −9.3% | −9.7% | −8.8% |
| Brain | 7.5 | 7.3 | −2.3% | −5.9% | 1.4% | 5.2 | 5.2 | −0.1% | −4.2% | 4.3% |
| Breast (females) | — | — | — | — | — | 134.3 | 121.3 | −9.7% | −10.4% | −8.9% |
| Cervix | — | — | — | — | — | 7.9 | 7.1 | −10.2% | −13.5% | −6.8% |
| Colorectal | 43.5 | 38.4 | −11.6% | −13.0% | −10.2% | 32.5 | 29.3 | −9.8% | −11.3% | −8.3% |
| Corpus and uterus | — | — | — | — | — | 28.6 | 26.3 | −7.9% | −9.5% | −6.3% |
| Esophagus | 7.3 | 6.9 | −5.4% | −8.8% | −1.9% | 1.8 | 1.6 | −7.8% | −13.9% | −1.2% |
| Hodgkin lymphoma | 3.0 | 2.8 | −7.2% | −12.7% | −1.5% | 2.4 | 2.2 | −7.3% | −13.3% | −0.9% |
| Kidney and RP | 24.9 | 22.7 | −8.7% | −10.6% | −6.9% | 12.4 | 11.0 | −11.5% | −13.9% | −9.1% |
| Larynx | 4.7 | 4.2 | −10.8% | −14.8% | −6.6% | 1.0 | 0.9 | −12.4% | −20.2% | −3.9% |
| Leukemia | 19.4 | 17.9 | −7.6% | −9.8% | −5.4% | 11.6 | 11.2 | −3.1% | −5.8% | −0.3% |
| Liver and IBD | 14.7 | 13.2 | −9.8% | −12.1% | −7.5% | 5.5 | 5.2 | −6.7% | −10.3% | −3.0% |
| Lung | 56.3 | 50.0 | −11.1% | −12.3% | −9.9% | 46.4 | 40.4 | −12.9% | −14.0% | −11.7% |
| Melanoma | 28.7 | 24.1 | −15.8% | −17.4% | −14.1% | 18.0 | 15.4 | −14.3% | −16.3% | −12.3% |
| Myeloma | 9.4 | 8.7 | −7.7% | −10.7% | −4.5% | 6.4 | 5.9 | −8.3% | −11.7% | −4.8% |
| NHL | 23.3 | 21.5 | −7.7% | −9.6% | −5.7% | 16.1 | 14.7 | −8.4% | −10.5% | −6.2% |
| Oral cavity and pharynx | 17.8 | 16.6 | −6.8% | −8.9% | −4.6% | 6.5 | 6.2 | −4.4% | −7.8% | −0.9% |
| Ovary | — | — | — | — | — | 10.4 | 9.6 | −7.4% | −10.1% | −4.6% |
| Pancreas | 15.6 | 15.0 | −4.3% | −6.7% | −1.9% | 12.2 | 11.7 | −3.9% | −6.3% | −1.4% |
| Prostate | 124.2 | 109.9 | −11.5% | −12.2% | −10.7% | — | — | — | — | — |
| Stomach | 9.1 | 8.4 | −8.3% | −11.3% | −5.1% | 5.4 | 4.8 | −10.5% | −14.1% | −6.8% |
| Testis | 6.0 | 6.0 | 0.7% | −3.4% | 5.0% | — | — | — | — | — |
| Thyroid | 7.8 | 6.7 | −14.0% | −17.1% | −10.7% | 21.1 | 17.4 | −17.9% | −19.7% | −16.0% |
| Urinary bladder | 31.9 | 30.1 | −5.7% | −7.4% | −4.0% | 8.0 | 7.2 | −9.4% | −12.2% | −6.4% |
Rates are per 100 000 population. We used SEER*Stat estimates of ratio = [rate (2020)/rate (2019)] and respective confidence interval (LCI, UCI). Percent change (PC) is calculated as (ratio − 1) × 100. The lower and upper limits of the confidence interval for PC are calculated as (UCI − 1) × 100 and (LCI − 1) × 100, respectively. CI = confidence interval; IBD = intrahepatic bile duct; NHL = non-Hodgkin lymphoma; RP = renal pelvis. Incidence rates were delay adjusted using the November 2021 submission delay adjustment factors (9). See site recode definition for details on cancer site codes: https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html.